The recombinant zoster vaccine (RZV) Shingrix demonstrated effectiveness in preventing herpes zoster (HZ) and postherpetic neuralgia among adults aged 50 years or older with rheumatoid arthritis (RA).

A target trial emulation was conducted to assess the effectiveness of recombinant zoster vaccine (RZV) accounting for prior receipt of live zoster vaccine (ZVL) and immunocompetence. The study found ...

Recombinant quadrivalent influenza vaccine (RIV4) and standard egg-based quadrivalent inactivated IV (IIV4) show comparable effectiveness in reducing influenza-related hospitalization among older ...

The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...

The global veterinary vaccines market is projected to grow from USD 11 billion in 2025 to USD 15.6 billion by 2031, ...

The induction of respiratory mucosal immunity, characterized by secretory IgA (sIgA) and lung-resident memory T (T RM) cells, is essential for establishing robust first-line defence against viruses.

Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead. Highlights Significant ...

Vaxart Inc. company and executive profile by Barron's. View the latest VXRT company infomation and executive bios.

Trivalent egg-based A/Thailand/8/2022 (H3N2) A/Croatia/10136RV/2023 (H3N2) H3N2 strain substituted Trivalent cell/recombinant A/Massachusetts/18/2022 (H3N2) A/District of Columbia/27/2023 (H3N2) H3N2 ...

Among older adults who received at least one dose of the recombinant shingles vaccine, vaccine effectiveness against any herpes zoster-related outcome was 56.1%. Getting a second dose yielded a ...

The global veterinary vaccines market is projected to grow from USD 11 billion in 2025 to USD 15.6 billion by 2031, registering a CAGR of 6% during ...